Earnings
Decibel Reports Full-Year and Fourth Quarter 2025 Results: Revenue Grows 22% to $113 Million, Issues 2026 Guidance
Decibel Cannabis Confirms AgMedica Integration Success, Extends Debt Maturity Through 2030
Executive Summary
- Full-Year 2025 Results: Net revenue grew 22% to $113 million; Adjusted EBITDA rose 29% to $23 million. Free Cash Flow surged 292% to $5.5 million.
- International Growth: International sales increased 484% year-over-year to $24 million, driven by AgMedica Bioscience Inc. integration.
- AgMedica Performance: The acquired entity contributed $7 million in Adjusted EBITDA for the full year, exceeding the initial $4 million target.
- 2026 Guidance: Company projects net revenue of $130 to $135 million (approx. 18% growth) and Adjusted EBITDA of $27 to $31 million (approx. 26% growth).
- Operational Updates: Creston, BC property sale agreement entered for $2.5 million; consolidation into Battleford, SK facility expected to save $4 million annually.
- Debt Refinancing: Closed a new $61 million credit facility on February 10, 2026, extending maturities to 2030 and reducing 2026 payment obligations by $5 million.
Material Impact
- Guidance Miss vs. Revision: The actual Full-Year 2025 revenue ($113M) and EBITDA ($23M) slightly missed the revised guidance provided in Q3 2025 (Revenue ~$115M, EBITDA ~$24M). This indicates minor execution variance against internal targets but remains within a narrow margin (~2%).
- Cash Flow Validation: The 292% surge in Free Cash Flow is the most material positive metric, confirming operational efficiency improvements and validating the debt refinancing strategy.
- Strategic Confirmation: The AgMedica integration exceeding EBITDA targets ($7M vs $4M) confirms the acquisition thesis was sound, reducing execution risk associated with M&A.
- Balance Sheet Health: The February 2026 debt extension and asset sale were previously announced material events; this earnings release serves as confirmation rather than introducing new capital or strategic shifts.
- Forward Outlook: 2026 guidance implies continued growth, but the slight miss on FY2025 targets suggests management may be conservative in future projections to ensure delivery.
DB · Price
Company Overview
- Company Profile: Decibel Cannabis Company Inc. operates in the cannabis sector with a focus on domestic brand growth and international cultivation/processing via AgMedica Bioscience Inc.
- Flagship Project: The integration of AgMedica Bioscience Inc., which provides international GACP cultivators and processing capacity (60 Tons per Annum).
- Domestic Brands: "Standard Issue" brand launched with early sell-through exceeding forecasts by 30%; refreshed vape portfolio including General Admission disposables.
- Facilities: Primary cultivation consolidated into Battleford, Saskatchewan; Creston, BC facility slated for sale to optimize footprint.
More from Decibel Cannabis Company Inc.
May 21, 2026 · 08:00